Potentiation of combined p19Arf and interferon-beta cancer gene therapy through its association with doxorubicin chemotherapy

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorIcahn School of Medicine at Mount Sinai-
Autor(es): dc.contributorInstituto de Pesquisas Tecnológicas (Bionano-IPT)-
Autor(es): dc.contributorWashington University School of Medicine-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorBiotecnologia Unidade 1-
Autor(es): dc.contributorVlaams Instituut Voor Biotenchnologie-UGent Center for Medical Biotechnology-
Autor(es): dc.creatorMedrano, Ruan F. V.-
Autor(es): dc.creatorSalles, Thiago A.-
Autor(es): dc.creatorDariolli, Rafael-
Autor(es): dc.creatorAntunes, Fernanda-
Autor(es): dc.creatorFeitosa, Valker A.-
Autor(es): dc.creatorHunger, Aline-
Autor(es): dc.creatorCatani, João P. P.-
Autor(es): dc.creatorMendonça, Samir A.-
Autor(es): dc.creatorTamura, Rodrigo E.-
Autor(es): dc.creatorLana, Marlous G.-
Autor(es): dc.creatorRodrigues, Elaine G.-
Autor(es): dc.creatorStrauss, Bryan E.-
Data de aceite: dc.date.accessioned2025-08-21T19:48:32Z-
Data de disponibilização: dc.date.available2025-08-21T19:48:32Z-
Data de envio: dc.date.issued2023-03-01-
Data de envio: dc.date.issued2023-03-01-
Data de envio: dc.date.issued2022-11-30-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1038/s41598-022-17775-y-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/241694-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/241694-
Descrição: dc.descriptionBalancing safety and efficacy is a major consideration for cancer treatments, especially when combining cancer immunotherapy with other treatment modalities such as chemotherapy. Approaches that induce immunogenic cell death (ICD) are expected to eliminate cancer cells by direct cell killing as well as activation of an antitumor immune response. We have developed a gene therapy approach based on p19Arf and interferon-β gene transfer that, similar to conventional inducers of ICD, results in the release of DAMPS and immune activation. Here, aiming to potentiate this response, we explore whether association between our approach and treatment with doxorubicin (Dox), a known inducer of ICD, could further potentiate treatment efficacy without inducing cardiotoxicity, a critical side effect of Dox. Using central composite rotational design analysis, we show that cooperation between gene transfer and chemotherapy killed MCA205 and B16F10 cells and permitted the application of reduced viral and drug doses. The treatments also cooperated to induce elevated levels of ICD markers in MCA205, which correlated with improved efficacy of immunotherapy in vivo. Treatment of subcutaneous MCA205 tumors associating gene transfer and low dose (10 mg/kg) chemotherapy resulted in inhibition of tumor progression. Moreover, the reduced dose did not cause cardiotoxicity as compared to the therapeutic dose of Dox (20 mg/kg). The association of p19Arf/interferon-β gene transfer and Dox chemotherapy potentiated antitumor response and minimized cardiotoxicity.-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
Descrição: dc.descriptionLaboratório de Vetores Virais Centro de Investigação Translacional Em Oncologia/LIM 24 Instituto do Câncer do Estado de São Paulo (ICESP) Faculdade de Medicina Universidade de São Paulo (FM-USP), Av. Dr. Arnaldo, 251, 8° Andar, SP-
Descrição: dc.descriptionLaboratório de Genética e Cardiologia Molecular/LIM 13 Instituto do Coração FM-USP, SP-
Descrição: dc.descriptionDepartment of Pharmacological Sciences Icahn School of Medicine at Mount Sinai-
Descrição: dc.descriptionNúcleo de Bionanomanufatura Instituto de Pesquisas Tecnológicas (Bionano-IPT), SP-
Descrição: dc.descriptionDepartment of Radiation Oncology Washington University School of Medicine-
Descrição: dc.descriptionDepartment of Microbiology Immunology and Parasitology Paulista School of Medicine Federal University of São Paulo (EPM-UNIFESP)-
Descrição: dc.descriptionDepartment of Pathology and Immunology Washington University School of Medicine-
Descrição: dc.descriptionFaculdade de Ciências Farmaceuticas Universidade Estadual Paulista Júlio de Mesquita Filho, SP-
Descrição: dc.descriptionCristalia Biotecnologia Unidade 1, Rodoviária SP 147, SP-
Descrição: dc.descriptionVlaams Instituut Voor Biotenchnologie-UGent Center for Medical Biotechnology-
Descrição: dc.descriptionDepartment of Biological Sciences Federal University of São Paulo, SP-
Descrição: dc.descriptionFaculdade de Ciências Farmaceuticas Universidade Estadual Paulista Júlio de Mesquita Filho, SP-
Descrição: dc.descriptionFAPESP: 15/26580-9-
Idioma: dc.languageen-
Relação: dc.relationScientific Reports-
???dc.source???: dc.sourceScopus-
Título: dc.titlePotentiation of combined p19Arf and interferon-beta cancer gene therapy through its association with doxorubicin chemotherapy-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.